3,5-二叔丁基-1,4-二甲基吡唑 | 141665-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3,5-二叔丁基-1,4-二甲基吡唑
• 英文名称: 1,4-dimethyl-3,5-di-tert-butyl-pyrazole
• 英文别名: 1,4-Dimethyl-3,5-di-t-butylpyrazole；3,5-ditert-butyl-1,4-dimethylpyrazole
• CAS: 141665-20-5
• 化学式: C₁₃H₂₄N₂
• 分子量: 208.347
• InChiKey: PNGZHMZNRTWVPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2,4,6,6-pentamethyl-3,5-heptanedione 、 甲基肼 以 乙醇 为溶剂， 以60%的产率得到3,5-二叔丁基-1,4-二甲基吡唑
  参考文献：
  名称：

  Basicity of C-substituted pyrazoles in the gas phase: an experimental (ICR) and theoretical study

  摘要：

  The experimental gas-phase proton affinities (PAs) of 32 N-H and N-methyl pyrazoles have been determined by means of Fourier transform ion cyclotron resonance spectroscopy (FTICR). Together with the previously reported PAs for 12 C-methyl-substituted pyrazoles, they provide a set of 57 data (counting each tautomer separately). The remarkably large spread of PAs, ca. 55 kcal.mol-1, makes this set most suitable for structural analyses. In a few cases, ab initio 6-31G//6-31G protonation energies were calculated and found to be linearly related to the experimental PAs to a very high degree of precision. A simple additive model of substituent effects on PAs (including substitutions at positions 3, 4, and 5) was found to hold, even for very crowded derivatives such as 1,4-dimethyl-3,5-di-tert-butylpyrazole (27). The only significant interaction appears between phenyl groups at positions 3 and 5. The statistically averaged substituent effects on PAs were successfully analyzed in terms of polarizability and field and resonance contributions, according to the Taft-Topsom model. Both positions 3 and 5 behave in a way similar to that of position 2 in the pyridines. From this interesting result it follows that, with the exception of 3-aminopyrazole, the tautomerism of pyrazoles is not very dependent of the nature of the 3(5)-substituent.

  DOI：

  10.1021/jo00040a040

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Lopez Omar D.

  公开号：US20110294819A1

  公开（公告）日：2011-12-01

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物，包括这些化合物的组合物以及抑制NS5A蛋白功能的方法。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS
  申请人：Oslob Johan D.

  公开号：US20110059976A1

  公开（公告）日：2011-03-10

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: and n, R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.
• US7767687B2
  申请人：——

  公开号：US7767687B2

  公开（公告）日：2010-08-03
• US8362020B2
  申请人：——

  公开号：US8362020B2

  公开（公告）日：2013-01-29